dataesr/scientific-paragraphs-categorization huggingface dataset:
5 % and ≥ 4. 5 % offers a sensible cut-off for "equipoise of PCI and CABG" or "CABG better," respectively  [10]. Statistical significance was defined as a two-sided p-value ≤0. 05. All analyses were performed using SPSS Statistics version 27 (IBM Corp. , Armonk, 281 N. Y. , USA) and R software version 3. 5. 1 (R Foundation for Statistical Computing, Vienna, Austria).
Funding This work was performed under the framework of the  Interdisciplinary Thematic Institute IMCBio , as part of the  ITI 2021e2028 program  of the  University of Strasbourg ,  CNRS  and  Inserm. It was supported by  IdEx Unistra  ( ANR-10-IDEX-0002 ), by  SFRI-STRAT'US  project ( ANR 20-SFRI-0012 ), and  EUR IMCBio  ( IMCBio   ANR-17-EURE-0023 ) under the framework of the  French Investments for the Future Program » , by previous  Labex NetRNA  ( ANR-10-LABX-0036 ) and by the  Fondation pour la Recherche M edicale (FRM)  (grant number  FDT201704337050 ) to  Marta Cela.
Acknowledgments It is a pleasure to acknowledge fruitful discussions with  Michel Labouesse  and  Kelly Molnar  about experimental observations concerning the embryonic C. elegans elongation. We also thank  Alain Goriely  for his help with the technical aspects of nonlinear elasticity. Both authors acknowledge the support of the contract  EpiMorph  ( ANR-2018-CE13-0008 ). Anna Dai  acknowledges the support of the  CSC (China Scholarship Council) , file No. 201906250173.
Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs. Results: Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies ( P ≤0.
OnCovid is one such registry including 37 centers from UK, Italy, Spain, France, Belgium, and Germany. It prospectively collected data from patients with cancer presenting with laboratory-confirmed COVID-19 and reports from this registry were previously published  [12] [13] [14] [15] [16] [17] [18] [19]. We employed this registry in combination with propensitymatched analysis to compare ICI therapy alone vs non-ICI SACT received within 4 weeks of COVID-19 diagnosis on outcomes in patients with cancer.
Methods In this retrospective analysis we utilized the OnCovid registry (NCT04393974) database to explore the potential association between previous exposures to chemotherapy-free ICI regimens and COVID-19 severity. Some methods employed to explore the On-Covid registry described in this study were published previously  [12] [13] [14] [15] [16] [17] [18] [19] [20]. A full description of the OnCovid study design and procedures is provided in Supplementary Methods. For details on data collection, refer to Supplementary Methods and Supplementary Table  1.
Clinical data and outcomes Variables related to key demographics and tumor characteristics were abstracted: country, sex, age, number of comorbidities, smoking status, primary tumor site, tumor stage, tumor status, and SARS-CoV-2 vaccination status (see Supplementary Methods for definition and Supplementary Table  2 ). Patients were observed from confirmation date of first SARS-CoV-2 infection until death or loss of follow-up. Patients that did not attend planned followup appointments scheduled by treating clinicians, for any reason, were considered lost to follow-up. Acknowledging the competing influence of the underlying malignancy in determining clinical outcomes, we elected the all-cause 14-day and 28-day case fatality rate as the clinical endpoints of interest, in an attempt to differentiate early (COVID-19-related) from late (cancer-related) mortality as consistently done in with our registry  [15 , 16 , 17 , 21].
Statistical analysis Baseline characteristics are reported using descriptive statistics. Categorical variables were analyzed using Fisher exact test and Pearson χ2 test as appropriate with estimation presented as unadjusted odds ratio and 95% CI. Median follow-up was calculated using reverse Kaplan-Meier method. PSM with a 1:3 ratio (ICI vs non-ICI) and caliper of 0. 2 was performed using MatchIt package in R with "nearest" method, to obtain comparable cohorts of ICI vs non-ICI SACT within 4 weeks before COVID-19 diagnosis, with balancing measured through postmatching standardized mean difference (SMD). Patients receiving ICIs were set as the reference group. Patients enrolled with the diagnosis of breast cancer were excluded from matching as none received ICI therapy. Patients were matched based on key variables: country (United Kingdom, Italy, Spain, others), sex (male vs female), age ( ≥65 vs < 65 years), number of comorbidities (0-2 vs > 2 comorbidities), primary tumor (gastrointestinal, gynecological/genitourinary, thoracic, hematologic, and other), tumor stage (advanced vs non-advanced), tumor status (active/progressive vs non-active/in remission), and vaccination status (fully/boosted vs partially/unvaccinated).
However, in an industry-conducted PSM study using a United States (US) database of more than 17,0 0 0 patients with cancer and COVID-19, ICI treatment in 228 patients within 90 days of COVID-19 infection had similar 30-day mortality and COVID-19 severity compared to a group of 456 patients matched on age, sex, region, smoking history, tumor type, and stage, and comorbidities  [23]. Another US-based study investigated a registry of more than 12,0 0 0 patients with cancer and COVID-19, adjusting for a range of variables  [24]. Of 599 registry patients administered some form of immunotherapy within 90 days of infection, 539 received an ICI. This study reported immunotherapy worsened COVID-19 severity or incidence of cytokine storm in patients with baseline immunosuppression. However, because almost 10% of immunotherapy patients received non-ICI therapy, including CAR-T cell therapy, its findings are difficult to interpret with regard to ICI therapy alone.
However, this study was very small with several investigators reporting potential competing interests. Other RCTs examining effects of early ICI therapy in patients presenting with COVID-19 are registered without results (NCT04413838, NCT04356508, NCT04343144, NCT04268537, EUCTR2020-001373-70-FR, IRCT20150303021315N19). This study and other large studies described above have limitations. Even with prospectively collected registries, subsequent analysis of registry data is retrospective. Additionally, the number of variables potentially confounding interpretation of effects of ICIs in cancer patients with COVID-19 is growing. ICI regimens are increasingly different with respect to agents, cellular targets, timing, and duration  [26 , 27]. In fact, one of the limitations of our study is missing information on duration of exposure to ICIs before COVID-19 diagnosis.
Additionally, the types and stages of cancer ICIs are used for are increasing. ICIs were predominantly used for the treatment of patients with lung cancer and unadjusted analysis showed no effect of ICI therapy on mortality or other severe outcomes in COVID-19 patients with thoracic malignancies  [28]. However, the present study finds decreased COVID-19-related hospitalizations and complications in ICI-treated patients, possibly highlighting changing practice patterns. Furthermore, strains of COVID-19 are changing as is vaccination status of cancer patients  [29] [30] [31] [32]. In a previous analysis of ICI patients from the OnCovid registry, vaccination appeared beneficial  [12]. Patients with cancer receiving ICIs are still a small proportion of those receiving SACT. It is possible no registry or database will provide the granularity and power to definitively assess risks or benefits of previous ICI therapy in this population.
Acknowledgments OnCovid study group investigators:  Joanne S Evans ,  Judith Swallow ,  Georgina Hanbury ,  Chris Chung ,  Meera Patel ,  Diego Ottaviani ,  Amani Chowdhury ,  Lee Cooper ,  Sarah Ahmed ,  Lucy Rogers ,  Samira Bawany ,  Saira Khalique ,  Ramis Andaleeb ,  Kris Doonga ,  Dolly Saorise ,  Eleanor Jones ,  Charlotte Moss ,  Beth Russell ,  Eleanor Apthorp ,  Sarah Townsend ,  Amanda Jackson ,  Angela Loizidou ,  Martine Piccart ,  Claudia A Cruz ,  Roxana Reyes ,  Elia Segui ,  Javier Marco-Hernández ,  Margarita Viladot ,  David Garcia Illescas ,  Nadia Saoudi ,  Oriol Mirallas ,  Elisa Roldán ,  Roser Fort-Culillas ,  Raquel Liñan ,  Nadia Harbeck ,  Rachel Wuerstlein ,  Franziska Henze ,  Sven Mahner ,  Ricard Mesia ,  Eudald Felip ,  Marc Cucurull ,  Anna Pous ,  Clara Maluquer ,  Federica Biello ,  Andrea Patriarca ,  Daniela Ferrante ,  Lorenza Scotti ,  Marco Krengly ,  Andrea Marrari ,  Armando Santoro ,  Federica Grosso ,  Vittorio Fusco ,  Sara Delfanti ,  Giuseppe Tonini ,  Alberto Zambelli ,  Vittoria Fotia ,  Lorenzo Chiudinelli ,  Michela Franchi ,  Michela Libertini ,  Rossella Bertulli ,  Salvatore Provenzano ,  Daniele Generali ,  Salvatore Grisanti ,  Valeria Tovazzi ,  Corrado Ficorella ,  Giampiero Porzio ,  Alessandro Parisi ,  Paola Queirolo ,  Maristella Saponara ,  Raffaele Giusti ,  Marco Filetti ,  Francesca Mazzoni ,  Federica Zoratto ,  Marco Tucci ,  Rossana Berardi ,  Luca Cantini ,  Annalisa Guida ,  Sergio Bracarda ,  Maria Iglesias ,  Ana Sanchez de Torre ,  Marta Perachino , and  Marco Tagliamento.
Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatmentfree remission (TFR) remains unclear. DAstop2 (ClinicalTrials. gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for ≥ one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for ≥1 year qualified for a second TKI stop. Ninetyfour patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2 nd stop.
Background: Mastocytosis and monoclonal mast cell (MC) activation syndrome (MMAS) are heterogeneous conditions characterized by the accumulation of atypical MCs. Despite the recurrent involvement of KIT mutations, the pathophysiologic origin of mastocytosis and MMAS is unclear. Although hereditary a-tryptasemia (HaT, related to TPSAB1 gene duplication) is abnormally frequent in these diseases, it is not known whether the association is coincidental or causal. Objective: We evaluated the prevalence of HaT in all mastocytosis subtypes and MMAS and assessed the pathophysiologic association with HaT. Methods: Clinical data, laboratory data, KIT mutations, TPSAB1 duplication (assessed by droplet digital PCR), and HaT prevalence were retrospectively recorded for all patients with mastocytosis and MMAS registered in the French national referral center database and compared to a control cohort.
Data collection All patients with mastocytosis included in this study fulfilling the World Health Organization 2016 diagnostic criteria of mastocytosis. The study data were collected by CEREMAST's medical staff using an electronic case report form. For all included patients, the following items of data were collected: sex; age at onset; age at diagnosis; family history of mastocytosis; type of mastocytosis; presence of 1 or more known symptoms of MCA (anaphylactic reactions, cutaneous involvement of mastocytosis, pruritus, flushes, urticaria, pollakiuria, diarrhea, abdominal pain, epigastric pain, nausea, reflux, asthenia, fatigue, chronic cough, dyspnea, bronchial hyperactivity, neuropsychological disorders [depression anxiety, insomnia, nightmares], neurological disorders [migraine, vertigo], bone/muscle/joint pains, and osteoporosis or osteopenia), baseline serum tryptase level, KIT sequence data, and TPSAB1 duplication (assessed by droplet digital PCR).
The sequencing products were then purified using the Sephadex G-50 (GE Healthcare) and a Multiscreen HTS plate (Merck Millipore, Darmstadt, Germany) and run on an ABI Prism 3730 Genetic Analyzer (Applied Biosystems). The sequences were analyzed using the SeqScape software (Applied Biosystems) by comparison with the NM_000222. 2 GenBank reference sequence (www. ncb. nlm. nih. gov). The whole KIT coding region corresponding to exons 8 to 13 was sequenced from a PCR amplification using the 1197S and 2029AS primers for 40 cycles at 988C for 5 seconds, 608C for 5 seconds, and 728C for 10 seconds. Then direct sequencing reactions were performed using the 1197S, 1678AS, 1595S, and 2029AS primers.
The aand b-tryptase copies were quantified using the QX-200 Droplet Reader and QuantaSoft software (Bio-Rad), as described elsewhere. E2  An elevated a-tryptase-encoding TPSAB1 copy number (consistent with HaT) was defined as > _3 a-tryptase copies or 2 a-tryptase copies in the presence of 3 b-tryptase copies.
Non-advSM included ISM, mastocytosis in the skin, BMM, cutaneous mastocytosis, and SSM. AdvSM included ASM, MC leukemia, sarcoma, and SM-AHN. *P <. 05. Prevalence of HaT in patients with advSM versus healthy controls. P value was calculated by chi-square or Fisher exact test. àPrevalence of HaT in patients with non-advSM versus advSM. P value was calculated by chi-square or Fisher exact test. INSERM's REACTing program, the French Ministry of Health's PHRC-N COVID-19 program (grant agreement PHRC-20-0242) and the European Commission's RECoVer program (grant agreement 101003589). Some authors received funding from the French National Research Agency (grant agreement Thera-CoV ANR-20-COVI-0018). L. P. was funded by the Bettencourt Schueller Foundation. 9. 6% (52). 43 Overall 14. 6% (1079) 11.
The proposed controller is an MIQP problem with multi-timescale rolling optimization. This problem can be solved using methods such as the cutting plane and branch and bound algorithms, which are available in commercial solvers, e. g. , CPLEX and GUROBI. In this study, the development and the simulation analysis have been conducted in MATLAB by using YALMIP/GUROBI. The optimization problems described in Section 5 with 24 h horizon are solved in 30 s at most on a workstation with a Xeon (R) 𝑄 -3395HQ 4. 9 GHz with memory size 256 GB.
The RTDS has different purposes: (i) it simulates all components of the MG and their real-time operations; (ii) it represents the central processing unit that manages and dispatches all physical/simulated quantities; (iii) it serves as a communication gateway with MATLAB to solve the optimization problems, as explained in Section 5. In order to ensure the third purpose, in real-time the RTDS sends the state variables of the system to MATLAB to be used as input for the optimization problems. The optimal schedule computed using MATLAB is then sent to each system component for their management. This type of connection between hardware components and RTDS is called hardware in the loop. Figs. [19] [20] [21] [22]  show the data profile used for the testing on the lab-scale setup, the powers, and the state of the storage devices, respectively.
with the help and the guidance of F. N. , I. C. and P. F. performed solid state multinuclear ( 1 H, 13 C, and 27 Al) NMR (ssNMR) Magic Angle Spinning (MAS) studies. N. G. M. , A. V. and M. D. performed, analyzed and discussed the IR experiments. N. H. and G. D. W. performed adsorption isotherm and the dynamic breakthrough curve measurements, calculated IAST selectivity and isosteric enthalpy of adsorption and contributed towards identifying the potential in CO2 capture processes. M. B. , A. A. M. and M. P. investigated the techno-economic analysis. G. M. and C. S. supervised the work and contributed towards the overall concept. Aknowledgements. The Authors acknowledge the European Union's  Horizon 2020 research and innovation programme  under grant agreement No. 831975  ( MOF4AIR  project) for providing financial support.
The High-Angle Annular Dark Field images were acquired with a Panther annular STEM detector using a convergent beam with an angle of 10. 5 mrad and a camera length of 330 mm. The EDX maps were taken with a Super X spectrometer equipped with four 30 mm 2 silicon drift detectors with a collection angle of 0. 7 srad. Data processing and arrangement have been performed with the Thermofisher proprietary software VELOX. XAS analyses have been performed at the beamline BM-08 LISA of the European Synchrotron Radiation Facility (Grenoble)  [53]. A fixed exit double crystal monochromator cooled at Liquid Nitrogen and equipped with Si (111) crystals was used for monochromating the beam whereas a pair of Si mirrors were used for beam collimation and focusing. The beam on the sample site was about 100 × 100 µm.
Data were collected in transmission mode using N 2 -filled ion chambers (IC), a reference foil was inserted after the second IC and its spectrum, read by a third IC was used as an energy reference. For the thermal treatment, the sample was inserted in a microtomo cell  [54]. Data were collected at the Iron K-edge (E = 7112 eV) to study its oxidation state, folding, and evolution during the pyrolysis process. For this reason, four sets of measurements have been performed. The samples have been analyzed in two atmospheres: Ar and Ar\H 2 , for each atmosphere in-situ and ex-situ measurements have been performed. In-situ spectra have been collected directly with the microtome cell, each 100 • C from room temperature (RT) to 800 • C and at 850 • C, with a continuous scan of 120 s. This upper temperature was limited by the heating element used within the microtome cell.
Ex-situ spectra have been collected in atmospheric conditions (e. g. exposed directly to air), after heating and cooling the sample in the desired atmosphere, in this case, the samples have been heated in steps of 100 • C in the range RT-1000 as described in the sample fabrication section. XANES and EXAFS spectra have been analyzed using the Athena software (Demeter Package)  [55]. X-ray photoelectron spectroscopy (XPS) was conducted on a Kratos AXIS Supra spectrometer with a monochromatic Al Kα source. The highresolution spectra were obtained using a pass energy of 20 eV at a 0. 1 eV step size. CasaXPS software was used to analyze the XPS data. All spectra were calibrated with respect to the sp 2 carbon at 284. 5 eV. A Linear background was employed for the C 1 s and N 1 s spectra, while a Shirley background was used for the Fe 2p spectra.
X-ray absorption spectroscopy XAS spectra for the speciation of Fe-based moieties during the development of Fe-N x -C under Ar or Ar/H 2 were recorded in both in-situ and ex-situ settings. XANES and EXAFS spectra have been analyzed using the Athena software (Demeter Package)  [55, 73]. The XANES spectra are shown in Fig. 4 , and the main features of FePc (1-5) are highlighted on the top axes. In Fig. 4 , XANES profiles of the FePc, on the upper plots, the spectra collected on samples pyrolyzed in Ar/H 2 atmosphere (Fig. 4(a  & b )), on the lower plot, the spectra collected on samples pyrolyzed in Ar atmosphere (Fig. 4(c  & d )). On the left, the data collected ex-situ, on the right, the data collected in-situ. In the insets, the region of the pre-peaks is highlighted. The first thing that can be observed, independently from the environment and the analysis condition (in-situ or ex-situ) is that the spectra undergo a significant change between 600 • C and 700 • C.
As shown by  [74] [75] [76] [77] , peaks 3-4 are related to 1 s→4pz transitions while peak 5 is related to 1 s→4px,y transition, even if in the ex-situ measurements their intensity is stable, in the in-situ experiments, it can be observed that their intensity changes, in particular peak 4 decreases, and the spectrum collected at 600 • C mostly resembles the spectrum of microcrystalline FePc  [76]. Instead in the pre-edge region, not only the pre-peaks 1 and 2 are observed, but also a third pre-peak (A), which is less intense in the in-situ spectra collected above 200 • C. To evaluate the effects of temperature on the symmetry change, a pre-peak fitting has been performed using Python (version 3. 10) lmfit (version 1. 1. 0) package  [78, 79]. The baseline has been fit with an atan function, while the peaks have been fit with five pseudo-Voigt functions.
Acknowledgments C. S. would like to thank the support from the  Italian Ministry of University and Research (MUR)  through the " Rita Levi Montalcini 2018" Fellowship  (Grant number  PGR18MAZLI ). C. S. would like to thank the support from  ENEA -UNIMIB  agreement ( Procedure 1. 1. 3 PNRR POR H2 ). C. S. would like to acknowledge the  Ministry of Foreign Affairs and International Cooperation -Directorate General for Cultural and Economic Promotion and Innovation (Italian Republic)  within the bilateral project  Italy-Israel  (WE-CAT). S. A. M. acknowledges a Ph. D. scholarship on Green Issues from action IV. 5 of the  PON Research and Innovation 2014-2020 "Education and research for recovery -REACT-EU" program. The experiment was carried out under the  ESRF  user program with experiment code CH-6246, we would like to thank  Dr Michela Brunelli  for assistance in the experiments.
LISA is a project funded by the  Consiglio Nazionale delle Ricerche  (project DFM. AD006. 072 ). After the embargo period, raw data will be available at the link https://doi. esrf. fr/10. 15151/ ESRF-ES-815015457. The authors acknowledge the use of facilities and instrumentation at the  UC Irvine Materials Research Institute (IMRI) , which is supported in part by the  National Science Foundation  through the  UC Irvine Materials Research Science and Engineering Center  ( DMR-2011967 ). XPS was performed at the  UC Irvine Materials Research Institute (IMRI)  using instrumentation funded in part by the  National Science Foundation   Major Research Instrumentation Program  under grant no. CHE-1338173.
One such system is described in Ref. [49] , where a decentralized robot collaborative UAV mapping system is proposed, utilizing a Distributed Ledger Technology (DLT) based network. In this system, each UAV can manage a synchronized database of confirmed transactions, which has several advantages compared to centralized systems. For instance, the map can be shared among the swarm even if a UAV joins or leaves, without the need for communication with a central station. Various strategies have been proposed to enhance the accuracy and robustness of map fusion in collaborative mapping systems. For instance, in Ref. [50] , the authors addressed the re-localization and map fusion problems in a multi-UAV SLAM system. The relocalization process was split into two stages: coarse relocalization on the server and fine re-localization on the UAV.
System-level design Numerous papers have proposed the design of vision-based collaborative positioning systems with different focuses. For example, in Ref. [59] , an adaptive collaborative visual-inertial SLAM system was proposed, which could adapt to different camera types such as monocular, stereo, or RGB-D cameras. The system measured the confidence of poses based on scene geometry consistency and pose observability, achieving higher accuracy in experiments on EuRoC datasets  [60]. In Ref. [61] , Karrer and Margarita proposed a visual-inertial collaborative SLAM system where keyframes containing keypoint position, keypoint descriptors, and spatial information were communicated through a keyframe buffer in the server. Once a loop was detected and matched, global optimization using feature matching was conducted, and the optimized poses were returned to the agents.